Nuvectis reports Q3 2026 results, advances ciprocopan and NXP200 toward US filings

Nuvectis Pharma reported third quarter 2026 results on November 4, 2026, describing a transformed pipeline following its in-licensing of ex-China rights to NXP100 and NXP200 from Haisco Pharmaceutical Group. The company's lead candidate, ciprocopan (NXP100), a once-daily oral Complement Factor B inhibitor, was approved in China in July 2026 for treating PNH patients who had not previously received complement inhibitors.¹

Nuvectis said discussions with the FDA on a U.S. regulatory path for ciprocopan in PNH are ongoing, with an update expected before year-end.¹ A second China marketing application for ciprocopan, covering PNH patients previously treated with anti-C5 therapy, is under review with approval expected in the first quarter of 2027, and the company also has an ongoing Phase 3 trial in IgAN and a Phase 2 study in lupus nephritis in China.¹ A Phase 3 head-to-head China study of ciprocopan versus eculizumab (Soliris) in complement-inhibitor-naive PNH patients was presented at the European Hematology Association 2026 conference, which the company said showed a robust efficacy advantage for ciprocopan.¹ Nuvectis plans to submit a U.S. IND for NXP100 by year-end.¹

For NXP200, its BRAF inhibitor, expanded Phase 1b glioma data as of a May 4, 2026 cutoff were presented at the 2026 ESMO Congress, covering 27 efficacy-evaluable patients with recurrent or progressive BRAF V600 glioma, including 20 with high-grade and 7 with low-grade disease.¹ The overall response rate was 40.0% in high-grade glioma, including three complete responses, and 42.9% in low-grade glioma, including one confirmed complete response.¹ A U.S. IND submission for NXP200 is also expected by year-end.¹

On finances, the company held $140.7 million in cash as of September 30, 2026, up from $31.6 million at the end of 2025.¹ Nuvectis said this cash position extends its runway into the second half of 2029.¹